Article

Gender-related Differences in Clinical Variables Associated with Survival of Patients with Atrial Fibrillation

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Average (ratings)
No ratings
Your rating

Disclosure:The authors have no conflicts of interest to declare.

Received:

Accepted:

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Abstract

Little is known about gender-related differences in clinical variables affecting the survival in inpatients with atrial fibrillation (AF). We recorded and compared clinical data and long-term mortality between 126 males and 124 females hospitalised with paroxysmal/persistent AF. Women were older and more symptomatic than men. Hypertension and renal dysfunction were more common in females, while dyslipidemia and smoking prevailed in males. Males were more likely to have a decreased left ventricular function and segmental wall motion abnormalities. On a median of a 39-month follow-up, mortality was comparable in males and females (p=0.6). Older age was significantly associated with poor survival in both groups. New-onset AF was significantly associated with shorter survival in males (Odds Ratio [OR] 3.35). In females, diabetes mellitus was significantly associated with increased mortality (OR 2.45), while statin treatment predicted better survival (OR 0.45). Gender-related differences in clinical characteristics were observed in inpatients with AF. Mortality was comparable in men and women. However, several clinical variables, which affect prognosis, were found sex-related.

To view the full article, please click on the PDF icon.

References

  1. Go AS, Hylek EM, Phillips KA, et al., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, JAMA, 2001;285:2370−5.
    Crossref | PubMed
  2. Miyasaka Y, Barnes ME, Gersh BJ, et al., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence, Circulation, 2006;114:119−25.
    Crossref | PubMed
  3. Lip GY, Tse HF, Management of atrial fibrillation, Lancet, 2007;370:604−18.
    Crossref | PubMed
  4. Benjamin EJ, Wolf PA, D'Agostino RB, et al., Impact of atrial fibrillation on the risk of death: the Framingham Heart Study, Circulation, 1998;98:946−52.
    Crossref | PubMed
  5. Wändell PE, Five-year mortality in men and women with atrial fibrillation, Scand J Prim Health Care, 2001;19:112−6.
    Crossref | PubMed
  6. Humphries KH, Kerr CR, Connolly SJ, et al., New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome, Circulation, 2001;103:2365−70.
    Crossref | PubMed
  7. Friberg J, Scharling H, Gadsbøll N, et al., Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study), Am J Cardiol, 2004;94:889−94.
    Crossref | PubMed
  8. Kaufman ES, Zimmermann PA, Wang T, et al., Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis, J Am Coll Cardiol, 2004;44:1276−82.
    Crossref | PubMed
  9. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al., Genderrelated differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study, J Am Coll Cardiol, 2005;46:1298−306.
    Crossref | PubMed
  10. Gomberg-Maitland M, Wenger NK, Feyzi J, et al., Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials, Eur Heart J, 2006;27:1947−53.
    Crossref | PubMed
  11. Dagres N, Nieuwlaat R, Vardas PE, et al., Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation, J Am Coll Cardiol, 2007;49:572−7.
    Crossref | PubMed
  12. Volgman AS, Manankil MF, Mookherjee D, Trohman RG, Women with atrial fibrillation: Greater risk, less attention, Gend Med, 2009;6:419−32.
    Crossref | PubMed
  13. Inoue H, Nozawa T, Hirai T, et al., Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACE, Circ J, 2010;74:650−4.
    Crossref | PubMed
  14. Potpara TS, Marinkovic JM, Polovina MM, et al., Genderrelated differences in presentation, treatment and longterm outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: The Belgrade atrial fibrillation study, Int J Cardiol, 2011 [Epub ahead of print].
  15. Levey AS, Coresh J, Greene T, et al., Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate, Ann Intern Med, 2006;145:247−54.
    Crossref | PubMed
  16. Dixon WJ, BMDP Statistical Software, Los-Angeles, CA: University of California Press;1993.
  17. Hnatkova K, Waktare JE, Murgatroyd FD, et al., Age and gender influences on rate and duration of paroxysmal atrial fibrillation, Pacing Clin Electrophysiol, 1998;21:2455−8.
    Crossref | PubMed
  18. Suttorp MJ, Kingma JH, Koomen EM, et al., Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function, Am J Cardiol, 1993;71:710−3.
    Crossref | PubMed
  19. Curtis AB, Gersh BJ, Corley SD, et al., Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study, Am Heart J, 2005;149:645−9.
    Crossref | PubMed
  20. Khumri TM, Idupulapati M, Rader VJ, et al., Clinical and echocardiographic markers in mortality risk in patients with atrial fibrillation, Am J Cardiol, 2007;99:1733−6.
    Crossref | PubMed
  21. Becker T, Kleemann T, Strauss M, et al., Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised, Clin Res Cardiol, 2008;97:74−82.
    Crossref | PubMed
  22. Watanabe E, Yamashita T, Suzuki S, et al., Statin treatment for patients with paroxysmal atrial fibrillation, Int Heart J, 2011;52:103−6.
    Crossref | PubMed
  23. Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, et al., New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey, Eur Heart J, 2008;29:1618−24.
    Crossref | PubMed
  24. Klem I, Wehinger C, Schneider B, et al., Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up, Diabetes Metab Res Rev, 2003;19:320−8.
    Crossref | PubMed
  25. Savage MP, Krolewski AS, Kenien GG, et al., Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor, Am J Cardiol, 1988;62:665−9.
    Crossref | PubMed
  26. Arboix A, Milian M, Oliveres M, et al., Impact of female gender on prognosis in type 2 diabetic patients with ischemic stroke, Eur Neurol, 2006;56:6−12.
    Crossref | PubMed
  27. Fauchier L, Pierre B, de Labriolle A, et al., Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials, J Am Coll Cardiol, 2008;51:828−35.
    Crossref | PubMed
  28. Sánchez-Quiñones J, Marín F, Roldán V, Lip GY, The impact of statin use on atrial fibrillation, QJM, 2008;101:845−61.
    Crossref | PubMed
  29. Lee YL, Blaha MJ, Jones SR, Statin therapy in the prevention and treatment of atrial fibrillation, J Clin Lipidol, 2011;5:18−29.
    Crossref | PubMed
  30. Jochmann N, Stangl K, Garbe E, et al., Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases, Eur Heart J, 2005;26:1585−95.
    Crossref | PubMed